Sentinel node biopsy in clinical stage I testicular cancer enables early detection of occult metastatic disease

被引:16
作者
Blok, Joost M. [1 ,2 ]
Kerst, J. Martijn [3 ]
Vegt, Erik [4 ]
Brouwer, Oscar R. [2 ]
Meijer, Richard P. [1 ,2 ]
Bosch, J. L. H. Ruud [1 ]
Bex, Axel [2 ]
van der Poel, Henk G. [2 ]
Horenblas, Simon [1 ,2 ]
机构
[1] Univ Med Ctr Utrecht, UMC Utrecht Canc Ctr, Dept Oncol Urol, Utrecht, Netherlands
[2] Netherlands Canc Inst, Dept Urol, Amsterdam, Netherlands
[3] Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands
[4] Netherlands Canc Inst, Dept Nucl Med, Amsterdam, Netherlands
关键词
non-seminomatous germ cell tumour; seminoma; sentinel lymph node biopsy; sentinel lymph node; testicular germ cell tumour; testicular neoplasms; #Testicular Cancer; #tscsm; #uroonc; GERM-CELL TUMORS; SURVEILLANCE; RISK; RELAPSE; SEMINOMA; GUIDELINES; DISSECTION; DIAGNOSIS;
D O I
10.1111/bju.14618
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Objectives To report the long-term results of the sentinel node (SN) approach in patients with clinical stage I testicular tumours in our facility. Patients and Methods We conducted an analysis of 27 consecutive patients suspected of clinical stage I testicular germ cell tumour (TGCT) and treated with an SN procedure at our tertiary referral centre. SNs were identified using lymphoscintigraphy with or without single-photo-emission computed tomography with CT (SPECT/CT). Patients underwent laparoscopic retroperitoneal SN excision with inguinal orchiectomy. Patients with a tumour-positive SN underwent adjuvant treatment. Follow-up was conducted according to then-current guidelines. Results In two patients, no SNs were visualized on scintigraphy. In the remaining 25 patients, a median (range) of 3 (1-4) SNs per patient were removed. Two patients showed no malignancy on histopathological examination of the testis. Of the 23 patients diagnosed with TGCT (16 seminomas, seven non-seminomas), three (13.0%) had occult metastatic disease. All 23 patients were without evidence of disease at a median (range) follow-up of 63.9 (29.0-143.4) months. Conclusion The SN procedure allows early identification of patients with occult metastatic disease in clinical stage I TGCT, enabling early treatment.
引用
收藏
页码:424 / 430
页数:7
相关论文
共 34 条
[1]   Risk factors for relapse in clinical stage I nonseminomatous testicular germ cell tumors: Results of the German Testicular Cancer Study Group Trial [J].
Albers, P ;
Siener, R ;
Kliesch, S ;
Weissbach, L ;
Krege, S ;
Sparwasser, C ;
Schulze, H ;
Heidenreich, A ;
de Riese, W ;
Loy, V ;
Bierhoff, E ;
Wittekind, C ;
Fimmers, R ;
Hartmann, M .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (08) :1505-1512
[2]   Guidelines on Testicular Cancer: 2015 Update [J].
Albers, Peter ;
Albrecht, Walter ;
Algaba, Ferran ;
Bokemeyer, Carsten ;
Cohn-Cedermark, Gabriella ;
Fizazi, Karim ;
Horwich, Alan ;
Laguna, Maria Pilar ;
Nicolai, Nicola ;
Oldenburg, Jan .
EUROPEAN UROLOGY, 2015, 68 (06) :1054-1068
[3]   Multicenter study evaluating a dual policy of postorchiectomy surveillance and selective adjuvant single-agent carboplatin for patients with clinical stage I seminoma [J].
Aparicio, J ;
del Muro, XG ;
Maroto, P ;
Paz-Ares, L ;
Alba, E ;
Sáenz, A ;
Terrasa, J ;
Barnadas, A ;
Almenar, D ;
Arranz, JA ;
Sánchez, M ;
Fernández, A ;
Sastre, J ;
Carles, J ;
Dorca, J ;
Gumà, J ;
Yuste, AL ;
Germà, JR .
ANNALS OF ONCOLOGY, 2003, 14 (06) :867-872
[4]   SPECT/CT and a Portable γ-Camera for Image-Guided Laparoscopic Sentinel Node Biopsy in Testicular Cancer [J].
Brouwer, Oscar R. ;
Olmos, Renato A. Valdes ;
Vermeeren, Lenka ;
Hoefnagel, Cornelis A. ;
Nieweg, Omgo E. ;
Horenblas, Simon .
JOURNAL OF NUCLEAR MEDICINE, 2011, 52 (04) :551-554
[5]   Robotic Primary RPLND for Stage I Testicular Cancer: a Review of Indications and Outcomes [J].
Chalfin, Heather J. ;
Ludwig, Wesley ;
Pierorazio, Phillip M. ;
Allaf, Mohamad E. .
CURRENT UROLOGY REPORTS, 2016, 17 (05)
[6]   STAGE-I NONSEMINOMATOUS GERM-CELL TESTICULAR-TUMOR - PREDICTION OF METASTATIC POTENTIAL BY PRIMARY HISTOPATHOLOGY [J].
FUNG, CY ;
KALISH, LA ;
BRODSKY, GL ;
RICHIE, JP ;
GARNICK, MB .
JOURNAL OF CLINICAL ONCOLOGY, 1988, 6 (09) :1467-1473
[8]   Risk-adapted treatment of clinical stage 1 non-seminoma testis cancer [J].
Klepp, O ;
Dahl, O ;
Flodgren, P ;
Stierner, U ;
Olsson, AM ;
Oldbring, J ;
Nilsson, S ;
Daehlin, L ;
Tornblom, M ;
Smaland, R ;
Starkhammar, H ;
Abramsson, L ;
Wist, E ;
Raabe, N ;
Edekling, T ;
CavallinStahl, E .
EUROPEAN JOURNAL OF CANCER, 1997, 33 (07) :1038-1044
[9]   Non-risk-adapted surveillance for patients with stage I nonseminomatous testicular germ-cell tumors: diminishing treatment-related morbidity while maintaining efficacy [J].
Kollmannsberger, C. ;
Moore, C. ;
Chi, K. N. ;
Murray, N. ;
Daneshmand, S. ;
Gleave, M. ;
Hayes-Lattin, B. ;
Nichols, C. R. .
ANNALS OF ONCOLOGY, 2010, 21 (06) :1296-1301
[10]   Patterns of Relapse in Patients With Clinical Stage I Testicular Cancer Managed With Active Surveillance [J].
Kollmannsberger, Christian ;
Tandstad, Torgrim ;
Bedard, Philippe L. ;
Cohn-Cedermark, Gabriella ;
Chung, Peter W. ;
Jewett, Michael A. ;
Powles, Tom ;
Warde, Padraig R. ;
Daneshmand, Siamak ;
Protheroe, Andrew ;
Tyldesley, Scott ;
Black, Peter C. ;
Chi, Kim ;
So, Alan I. ;
Moore, Malcom J. ;
Nichols, Craig R. .
JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (01) :51-57